Imunon, Inc. (IMNN)
Imunon, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Lawrenceville, NJ, US. The stock last traded at $1.63, up 1.24% on the session, giving a market capitalisation of $6.8M. On trailing twelve-month figures it carries a trailing P/E of -0.36, a net margin of 0.0%. Its beta of 1.97 implies it has historically moved more than the broad market.
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
Imunon, Inc. is most often compared with the following Healthcare names: